How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...
New Scientist on MSN
What is 'SpudCell'? Arguably the greatest bioengineering feat yet
A prototype cell partly capable of replicating itself has been created using 36 existing bacterial genes, but it's not really ...
Your institution does not have access to this book on JSTOR. Try searching on JSTOR for other items related to this book. https://doi.org/10.2307/j.ctvjnrt76.5 https ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results